<MedlineCitation Status="Completed">
<MedlineID>10011450</MedlineID>
<PMID>369611</PMID>
<DateCreated>
<Year>1979</Year>
<Month>05</Month>
<Day>26</Day>
</DateCreated>
<DateCompleted>
<Year>1979</Year>
<Month>05</Month>
<Day>26</Day>
</DateCompleted>
<DateRevised>
<Year>2000</Year>
<Month>12</Month>
<Day>18</Day>
</DateRevised>
<Article>
<Journal>
<ISSN>0006-3002</ISSN>
<JournalIssue>
<Volume>566</Volume>
<Issue>2</Issue>
<PubDate>
<Year>1979</Year>
<Month>Feb</Month>
<Day>9</Day>
</PubDate>
</JournalIssue>
</Journal>
<ArticleTitle>An essential arginyl residue in yeast hexokinase.</ArticleTitle>
<Pagination>
<MedlinePgn>296-304</MedlinePgn>
</Pagination>
<Abstract>
<AbstractText>The inactivation of yeast hexokinase A (ATP:D-hexose 6-phosphotransferase, EC 2.7.1.1) by phenylglyoxal obeys pseudo first-order kinetics. Formation of a reversible enzyme-reagent complex prior to modification is suggested by the observed saturation kinetics. Loss of activity correlates with the incorporation of 1 mol of [14C]phenylglyoxal per mol 50 000 dalton subunit. No significant conformational change occurs concomitantly. Inactivation is attributable to modification of an arginyl residue. The pattern of protection by substrates and analogs favors an interaction of this essential residue with the terminal phosphoryl group of ATP or glucose 6-phosphate.</AbstractText>
</Abstract>
<AuthorList>
<Author>
<LastName>Philips</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
<Author>
<LastName>Pho</LastName>
<ForeName>D B</ForeName>
<Initials>DB</Initials>
</Author>
<Author>
<LastName>Pradel</LastName>
<ForeName>L A</ForeName>
<Initials>LA</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType>Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo>
<Country>NETHERLANDS</Country>
<MedlineTA>Biochim Biophys Acta</MedlineTA>
<NlmUniqueID>0217513</NlmUniqueID>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance>Macromolecular Systems</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>107-22-2</RegistryNumber>
<NameOfSubstance>Glyoxal</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>50-99-7</RegistryNumber>
<NameOfSubstance>Glucose</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>56-65-5</RegistryNumber>
<NameOfSubstance>Adenosine Triphosphate</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>74-79-3</RegistryNumber>
<NameOfSubstance>Arginine</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.1.1</RegistryNumber>
<NameOfSubstance>Hexokinase</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName>Adenosine Triphosphate</DescriptorName>
<QualifierName>analogs &#38; derivatives</QualifierName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName MajorTopicYN="Y">Arginine</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Binding Sites</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Glucose</DescriptorName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Glyoxal</DescriptorName>
<QualifierName>analogs &#38; derivatives</QualifierName>
<QualifierName>pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Hexokinase</DescriptorName>
<QualifierName MajorTopicYN="Y">antagonists &#38; inhibitors</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Kinetics</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Macromolecular Systems</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Saccharomyces cerevisiae</DescriptorName>
<QualifierName MajorTopicYN="Y">enzymology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName>Structure-Activity Relationship</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
